1. Home
  2. AGIO vs VRRM Comparison

AGIO vs VRRM Comparison

Compare AGIO & VRRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$35.65

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Logo Verra Mobility Corporation

VRRM

Verra Mobility Corporation

HOLD

Current Price

$4.46

Market Cap

2.0B

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGIO
VRRM
Founded
2007
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Transportation Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
2.0B
IPO Year
2013
2016

Fundamental Metrics

Financial Performance
Metric
AGIO
VRRM
Price
$35.65
$4.46
Analyst Decision
Buy
Buy
Analyst Count
8
5
Target Price
$38.88
$25.90
AVG Volume (30 Days)
1.0M
12.9M
Earning Date
04-29-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
347.37
EPS
N/A
0.17
Revenue
$43,011,000.00
$132,969,000.00
Revenue This Year
$76.75
$6.84
Revenue Next Year
$170.73
$6.88
P/E Ratio
N/A
$26.29
Revenue Growth
N/A
14.61
52 Week Low
$22.24
$3.40
52 Week High
$46.00
$25.83

Technical Indicators

Market Signals
Indicator
AGIO
VRRM
Relative Strength Index (RSI) 74.22 24.82
Support Level $26.71 $3.40
Resistance Level $36.07 $24.98
Average True Range (ATR) 1.44 0.33
MACD 0.79 0.31
Stochastic Oscillator 98.76 38.00

Price Performance

Historical Comparison
AGIO
VRRM

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

About VRRM Verra Mobility Corporation

Verra Mobility Corp is a provider of smart mobility technology solutions, principally operating throughout the United States, Australia, Europe, and Canada. The company develops and uses technology and data intelligence to help make transportation safer and easier. It operates in three reportable segments: Commercial Services, Government Solutions, and Parking Solutions. Maximum revenue is generated from the Commercial Services segment, which offers toll and violation management solutions and title and registration services for commercial fleet customers, including RACs and FMCs in North America. In Europe, it provides tolling and violations processing services.

Share on Social Networks: